A randomised double blind controlled trial of oral ephedrine/etilefrine in the prevention of recurrent (stuttering) attacks of priapism in sickle cell disease: a multicentre international study in older children and adults

Aintree University Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 320 人开始时间: 2006年2月2日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Male patients with a documented history of sickle cell disease (SCD) irrespective of genotype (alpha thalassemia status will not be determined)
•2. Patients should be 12 years or over
•3. Patients with a known history of stuttering priapism (a short self limiting episode lasting up to 4 hours which tends to be recurrent) attributable to SCD
•4. Patients in active attendance at a designated care centre i.e. one visit in the last six months
•5. Patients on a stable dose of hydroxyurea for over six months before trial entry, provided a baseline event rate (on treatment) is established before randomisation and no dose change occurs during trial period
•6. Patients who received a one-off or isolated top up transfusion greater than three months before recruitment date can be entered into study

•1. Patients with sickle cell trait (haemoglobin A greater than haemoglobin S on alkaline gel electrophoresis or high performance liquid chromatography (HPLC) will not be eligible for randomisation
•2. Patients known to have elevated blood pressure or a history of cardiac disease
•3. Patients with SCD and a documented history of stroke in the past
•4. Patients with a history of acquired vessel aneurysm in the past
•5. Patients known to be on MAOI (monoamine oxidase inhibitor) drugs or other drugs with significant interactions with study drugs
•6. Patients known to be intolerant of adrenergic drugs
•7. Patients with hyperthyroidism
•8. Patients on a long-term blood transfusion programme to prevent or treat the complications of SCD

发起方

Aintree University Hospitals NHS Foundation Trust (UK)